The purpose of this study is to determine if the drug empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.
The purpose of this study is to understand the ability of genetic testing to identify familial hypercholesterolemia among patients with acute cardiac event in hospital settings and to investigate the impact of genetic diagnosis on physician behaviour, medication use and decreasing cholesterol to an acceptable level.
The purpose of this study is to investigate if and how retinal blood vessels change after a spinal cord injury (SCI) and the associations of these changes with cardiovascular diseases. Using images of retinal blood vessels, we will develop a deep learning-based screening tool for autonomic dysreflexia, a cardiovascular complication unique to SCI.
The purpose of this study is to investigate whether Electrical Vestibular Stimulation (EVS) can lessen orthostatic hypotension in Parkinson’s disease patients. We aim to determine if individual precision-designed EVS stimulus can be optimized for improvements in hypotension.
The purpose of this study it to examine the safety and efficacy of gene-modified T cell therapy in patients who have previously received the treatment.
The purpose of the study is to find the best technique and tools for gaining access to left and right heart arteries using x-rays that show blood flow, in patients who are having a specific Medtronic heart valve inserted.
The purpose of the study is to determine the safety and effectiveness of the drug TQJ230 to lower Lipoprotein(a) to reduce cardiovascular events in patients with a history of heart disease.
The purpose of the study is to provide data demonstrating the safety and effectiveness of the PulseSelect™ PFA System for the treatment of atrial fibrillation.
The purpose of this study is to determine if the drug empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.
The purpose of the study is to evaluate the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.
The purpose of this study is to evaluate the safety and efficacy of CC-97540 CAR-T cell treatment for subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.
The purpose of the study is to compare differences in blood flow and valve pressures by two different methods in patients who are having transcatheter aortic valve replacement.
The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.
The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.
The purpose of this study is to evaluate the safety of etripamil nasal spray in patients with Paroxysmal Supraventricular Tachycardia (PSVT).
The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
The purpose of this study is to determine whether treatment with Blinatumomab is effective in reducing the risk of acute lymphoblastic leukemia returning in patients with residual cancer cells remaining in the body after stem cell transplant.
Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature coronary artery disease. The goal of this initiative is to create a registry of subjects with FH across Canada. The registry will help clinicians and researchers to determine the burden of disease and the long-term effects of treatment.
The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction
Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure. The MANTA device is expected to seal the femoral access puncture in less than 1 minute. This may result in less blood loss and a shorter time to walking compared to alternative closure means. Use of the MANTA device in this study is experimental. All other parts of the procedure involve standard medical care